Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Canopy Growth ( (TSE:WEED) ) is now available.
Canopy Growth’s German vaporization subsidiary Storz & Bickel, a global leader in high-end, medically certified cannabis vaporizers, is undergoing a leadership transition after 25 years under co-founder Jürgen Bickel. The company, renowned for its innovation, product quality, and ISO 13485-certified medical devices, is a key pillar of Canopy’s hardware offering within the broader cannabis ecosystem.
Storz & Bickel has appointed long-time executive David Männer as Managing Director effective April 1, 2026, succeeding outgoing co-founder Bickel. Canopy Growth CEO Luc Mongeau framed the change as a springboard to deepen Storz & Bickel’s U.S. presence and accelerate product innovation, signaling continuity in culture and operations while positioning the unit for its next phase of global growth.
The most recent analyst rating on (TSE:WEED) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.
Spark’s Take on WEED Stock
According to Spark, TipRanks’ AI Analyst, WEED is a Neutral.
The score is held back primarily by weak financial performance (shrinking revenue, persistent losses, and negative cash flow) and bearish technicals (below key moving averages with negative MACD). These are partially offset by a more positive earnings-call outlook centered on cost reductions, improved liquidity, and guidance toward positive adjusted EBITDA in FY2027, while valuation remains constrained due to continued losses and no dividend.
To see Spark’s full report on WEED stock, click here.
More about Canopy Growth
Canopy Growth is a world-leading cannabis company focused on improving lives through medical and adult-use cannabis products and services. Its portfolio spans Canadian consumer brands such as Tweed, 7ACRES, DOJA, Deep Space, Claybourne, MTL Cannabis, Low Key by MTL, and R’belle, alongside category-defining vaporization devices from German subsidiary Storz & Bickel.
The company is Canada’s leading provider of medical cannabis services through clinic network Canada House Clinics and online distributor Abba Medix, serving patients domestically and abroad. Canopy Growth also maintains strategic exposure to the U.S. THC market via Canopy USA, whose holdings include Acreage Holdings, Wana-branded edibles businesses, and Lemurian, a California-based producer of cannabis extracts and vape technology.
Storz & Bickel GmbH, based in Tuttlingen, Germany, is a global leader in high-end and medically certified cannabis vaporizers. Recognized for innovation, quality, and compliance, it holds ISO 13485 certification for medical devices and has won technical innovation awards, underpinning its role as a benchmark in vaporization technology for medical cannabis use.
Average Trading Volume: 2,170,033
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$512.4M
See more insights into WEED stock on TipRanks’ Stock Analysis page.